Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.56 |
| ▸ | GSTP1 | P09211 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4544345 | 0.88 | SMPD1 (0.59) | SMPD1GSTP1NPC1RAB9AL3MBTL1 | |
| SCHEMBL8378803 | 0.85 | CHRM4 (0.50) | NPC1RAB9AL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL20286381 | 0.83 | RAB9A (0.52) | NPC1RAB9AL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL27495196 | 0.82 | SMPD1 (0.56) | SMPD1GSTP1NPC1RAB9AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL8375536 | 0.81 | SMPD1 (0.55) | SMPD1GSTP1NPC1RAB9AL3MBTL1 | |
| SCHEMBL14996568 | 0.80 | ABCB1 (0.41) | SMPD1L3MBTL1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL1416805 | 0.80 | ALDH1A1 (0.48) | NPC1RAB9AMAPTTDP1CYP1A2 | |
| SCHEMBL1416869 | 0.80 | RAB9A (0.40) | SMPD1NPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL2969822 | 0.78 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2MAPTTDP1 | |
| SCHEMBL12004015 | 0.78 | MAOB (0.42) | SMPD1ABCG2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3555055-B1 | HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2022-08-03 | — | — | EP | disclosed |
| US-10864211-B2 | Hydroxy isoxazole compounds useful as GPR120 agonists | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3555055-A1 | HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS | Merck Sharp & Dohme Corp. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190269679-A1 | HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2018111734-A1 | HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-06-21 | — | — | WO | disclosed |
| EP-2098517-B1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | MSD KK (JP) | 2013-12-18 | — | — | EP | disclosed |
| US-8367708-B2 | Phenyl-isoxazol-3-ol derivative | MSD K.K. (JP) | 2013-02-05 | — | — | US | disclosed |
| EP-2298750-A1 | NOVEL ISOXAZOLE DERIVATIVE | MSD K.K. (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20110065739-A1 | NOVEL ISOXAZOLE DRIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
| US-20100130559-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2098517-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10864211-B2 | Hydroxy isoxazole compounds useful as GPR120 agonists | GPR119, GPR88, GPR180 | SMPD1 2505/4885GSTP1 2727/4885NPC1 445/4885 |
| US-20100130559-A1 | NOVEL PHENYL-ISOXAZOL-3-OL DERIVATIVE | GPR119, FFAR3, FFAR2 | SMPD1 2416/4885GSTP1 3424/4885NPC1 451/4885 |
| US-20110065739-A1 | NOVEL ISOXAZOLE DRIVATIVE | GPR119, GPR132, GPR180 | SMPD1 1370/4885GSTP1 3927/4885NPC1 910/4885 |
| US-20190269679-A1 | HYDROXY ISOXAZOLE COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR88, GPR180 | SMPD1 2505/4885GSTP1 2727/4885NPC1 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.